TY - JOUR
T1 - Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement
T2 - the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design
AU - Siami, Paul
AU - Roehrborn, Claus
AU - Barkin, Jack
AU - Damiao, Ronaldo
AU - Wyczolkowski, Marek
AU - Duggan, Annette
AU - Major-Walker, Kim
AU - Morrill, Betsy B.
N1 - Funding Information:
This study was fully funded by GlaxoSmithKline.
PY - 2007/11
Y1 - 2007/11
N2 - Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.
AB - Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.
KW - 5-alpha-reductase inhibitors
KW - Alpha adrenergic antagonist
KW - BPH
KW - Clinical trial
KW - DHT
KW - Prostate
KW - Prostate enlargement Combination drug therapy
KW - Prostate-specific antigen
KW - Prostatic hyperplasia
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=34848860581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848860581&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2007.07.008
DO - 10.1016/j.cct.2007.07.008
M3 - Article
C2 - 17761460
AN - SCOPUS:34848860581
SN - 1551-7144
VL - 28
SP - 770
EP - 779
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
IS - 6
ER -